ABCL-544: Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): 2 Year Follow-Up of the Phase 3 STARGLO Trial.

Jeremy S. Abramson, Matthew Ku, Mark Hertzberg, Christopher P. Fox, Charles Herbaux, Hui-Qiang Huang, Dok Hyun Yoon, Won Seog Kim, Huilai Zhang, Haifaa Abdulhaq, William Townsend, Estefania Mulvihill, Victor Orellana-Noia, Richard Ta, Huang Huang, Martine Joanna Kallemeijn, Anton Belousov, Alessia Bottos, Linda Lundberg, Gareth P. Gregory. ABCL-544: Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): 2 Year Follow-Up of the Phase 3 STARGLO Trial. Clinical Lymphoma Myeloma & Leukemia. 2025 Sep 1; 25:s745.

2025
https://researcherprofiles.org/profile/673092200

Jeremy S. Abramson, Matthew Ku, Mark Hertzberg, Christopher P. Fox, Charles Herbaux, Hui-Qiang Huang, Dok Hyun Yoon, Won Seog Kim, Huilai Zhang, Haifaa Abdulhaq, William Townsend, Estefania Mulvihill, Victor Orellana-Noia, Richard Ta, Huang Huang, Martine Joanna Kallemeijn, Anton Belousov, Alessia Bottos, Linda Lundberg, Gareth P. Gregory